Pharmacogenomics

Annals of Oncology

Volumn 18, Issue SUPPL. 9, 2007, Pages

  Marsh, S ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PLATINUM COMPLEX; RNA; THIOPURINE METHYLTRANSFERASE; GLUCURONOSYLTRANSFERASE; UDP GLUCURONOSYLTRANSFERASE, UGT1A8; UDP-GLUCURONOSYLTRANSFERASE, UGT1A8; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DIARRHEA; DNA FLANKING REGION; DNA POLYMORPHISM; DOSE CALCULATION; DRUG RESPONSE; ETHNIC DIFFERENCE; EXCISION REPAIR; EXON; GENE AMPLIFICATION; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCATION; GENE SEQUENCE; GENETIC DATABASE; HAPLOTYPE; HUMAN; INTRON; MEDICAL LITERATURE; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOMATIC MUTATION; CLINICAL MEDICINE; DNA SEQUENCE; GENETIC POLYMORPHISM; GENETICS; ISOLATION AND PURIFICATION; MUTATION; PHARMACOGENETICS; REVIEW;

CLINICAL MEDICINE; DATABASES, GENETIC; DNA, NEOPLASM; GLUCURONOSYLTRANSFERASE; HUMANS; MUTATION; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA;

EID: 36049009088     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm289     Document Type: Conference Paper

References (50)

1. Wiffen P, Gill M, Edwards J, Moore A. Adverse drug reactions in hospital patients Bandolier Extra. 2002 http://www.jr2.ox.ac.uk/bandolier/ Extraforbando/ADRPM.pdf.
2. Schrag D. Tha price tag on progress - chemotherapy for colorectal cancer. N Engl J Med 2004; 351: 317-319.
3. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549.
4. Freimuth RR, Ameyaw M-M, Pritchard SC et al. High-throughput Genotyping Methods for Pharmacogenomic Studies. Current Pharmacogenomics 2004; 2: 21-33.
5. Syvanen AC. Toward genome-wide SNP genotyping. Nat Genet 2005; 37S: S5-10.
6. Kwok PY. Methods for genotyping single nucleotide polymorphisms. Annu Rev Genomics Hum Genet 2001; 2: 235-258.
7. Innocenti F (ed). Pharmacogenomics Methods and Applications. Humana Press 2005.
8. McLeod HL, Marsh S. Pharmacogenetics goes 3D. Nat Genet 2005; 37: 794-795.
9. Lenz HJ. The use and development of germline polymorphisms in clinical oncology. J Clin Oncol 2004; 22: 2519-2521.
10. Yu J, Shannon WD, Watson MA, McLeod HL. Gene expression profiling of the irinotecan pathway in Golorectal cancer. Clin Cancer Res 2005; 11: 2053-2062.
11. Cheng Q, Yang W, Raimondi SC et al. Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet 2005; 37: 878-882.
12. Stebbing J, Bower M, Syed N et al. Epigenetics: An emerging technology in the diagnosis and treatment of cancer. Pharmacogenomics 2006; 7: 747-757,
13. Marsh S, Mallon MA, Goodfellow P, McLeod HL. Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. Pharmacogenomics 2005; 6: 873-877.
14. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999; 286: 487-491.
15. Marsh S, Pharmacogenetics of colorectal cancer, Expert Opin Pharmacother 2005; 6: 2607-2616.
16. Hoskins JM, Mcleod HL. Cancer Pharmacogenetics: The Move from Pharmacokinetics to Pharmacodynamics. Current Pharmacogenomics 2006; 4: 39-46.
17. Marsh S, Van Booven DJ, McLeod HL. Global pharmacogenetics: Giving the genome to the masses. Pharmacogenomics 2006; 7: 625-631.
18. Engen RM, Marsh S, Van Booven DJ, McLeod HL. Ethnic differences in pharmacogenetically relevant genes. Curr Drug Targets 2006; 7: 1641-1648.
19. Marsh S, Kwok P, McLeod HL. SNP databases and pharmacogenetics: Great start, but a long way to go. Hum Mutat 2002; 20: 174-179.
20. Bhatti P, Church DM, Rutter JL et al. Candidate single nucleotide polymorphism selection using publicly available tools: A guide for epidemiologists. Am J Epidemiol 2006; 164: 794-804.
21. Altshuler D, Brooks LD, Chakravarti A et al. A haplotype map of the human genome. Nature 2005; 437: 1299-1320.
22. Freimuth RR, Xiao M, Marsh S et al. Polymorphism discovery in 51 chemotherapy pathway genes. Hum Mol Genet 2005; 14: 3595-3603.
23. Paez JG, Janne PA, Lee JC et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science 2004; 304: 1497-1500.
24. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
25. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311.
26. Relling MV, Hancock ML, Rivera GK et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91: 2001-2008.
27. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 2002; 3: 89-98.
28. Nackley AG, Shabalina SA, Tchivileva IE et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006; 314: 1930-1933.
29. Wang D, Sadee W. Searching for polymorphisms that affect gene expression and mRNA processinig: Example ABCB1 (MDR1). Aaps J 2006; 8: E515-520.
30. Viguier J, Boige V, Miquel C et al. ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer. Clin Cancer Res 2005; 11: 6212-6217.
31. Stoehlmacher J, Park DJ, Zhang W et al. A multivariate analysis of genomic polymorphisms: Predicton of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004; 91: 344-354.
32. Kang S, Ju W, Kim JW et al. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 2006; 38: 320-324.
33. Bao L, Zhou M, Wu L et al. PolymiRTS Database: Linking polymorphisms in microRNA target sites with complex traits. Nucleic Acids Res 2007; 35: D51-54.
34. Wei X, McLeod HL, McMurrough J et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996; 98: 610-615.
35. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002; 12: 555-558.
36. Marsh S. Thymidylate synthase pharmacogenetics, Invest New Drugs 2005; 23: 533-537.
37. Villafranca E, Okruzhnov Y, Dominguez MA et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001; 19: 1779-1786.
38. McLeod HL, Tan B, Malyapa R et al. Genotype-guided neoadjuvant therapy for rectal cancer. Proc Am Soc Clin Oncol 2005; 23: 197.
39. Ulrich CM, Bigler J, Velicer CM et al. Searching expressed sequence tag databases: Discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 2000; 9: 1381-1385.
40. Mandola MV, Stoehlmacher J, Zhang W et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intraturnoral TS mRNA levels. Pharmacogenetcs 2004; 14: 319-327.
41. Bosma PJ, Chowdhury JR, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 1171-1175.
42. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998; 95: 8170-8174.
43. Innocenti F, Undevia SD, Iyer L et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-1388.
44. Invader UGT1A1 molecular assay for irinotecan toxicity. A genetic test for an increased risk of toxicity from the cancer chemotherapy drug irinotecan(Camptosar). Med Lett Drugs Ther 2006; 48: 39-40.
45. Ratain MJ. From bedside to bench to bedside to clinical practice: An odyssey with irinotecan. Clin Cancer Res 2006; 12: 1658-1660,
46. McLeod HL, Drug pathways: Moving beyond single gene pharmacogenetics. Pharmacogenomics 2004; 5: 139-141.
47. Sal K, Saeki M, Saito Y et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004; 75: 501-515.
48. de Jong FA, cle Jonge MJ, Verweij J, Mathijssen RH. Role of pharmacogenetics in irinotecan therapy. Cancer Lett 2006; 234: 90-106.
49. Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 2004; 5: 835-843.
50. de Jong FA, Scott-Horton TJ, Kroetz DL et al. Irinotecan-induced diarrhea: Functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 2007; 81: 42-49.